19.02.2013 Views

4th EucheMs chemistry congress

4th EucheMs chemistry congress

4th EucheMs chemistry congress

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Poster Session 2<br />

s1313<br />

chem. Listy 106, s257–s1425 (2012)<br />

Poster session 2 - organic <strong>chemistry</strong><br />

P - 0 9 0 1<br />

SynthetiC StudieS towArd SeLeCtive And<br />

StABLe inhiBitorS of dnA PoLyMerASe ALPhA:<br />

CArBoCyCLiC AnALoGS of dehydroALtenuSin<br />

S. KovACovA 1 , K. PAruCh 1<br />

1 Masaryk University, Department of Chemistry, Brno, Czech<br />

Republic<br />

DNA polymerases play a key role in replication and<br />

maintaining of genome stability and some of them can help cancer<br />

cells tolerate DNA damage. Their selective inhibition is therefore<br />

considered viable strategy for therapeutic intervention in<br />

oncology. [1] Accordingly, depletion of DNA polymerase alpha (pol<br />

alpha) combined with inhibition of CHK1 kinase afforded<br />

synthetic lethal phenotype in cancer cells. [2]<br />

Dehydroaltenusin is virtually the only known<br />

sub-micromolar selective inhibitor of pol alpha [3] that exhibited<br />

in vivo biological activity (include mice HeLa xenograft model). [4]<br />

However, the mechanism of action and potential usefulness of<br />

dehydroaltenusin are rather questionable as the compound is<br />

unstable and in polar solvents it exists as equilibrium mixture of<br />

two species: tricyclic lactone and its spirocyclic isomer. [5]<br />

We have prepared racemic carbocyclic analogs of both<br />

forms of dehydroaltenusin. The target structures as well as some<br />

of the key intermediates contain novel, potentially useful<br />

pharmacophores. As the compounds are chemically stable, they<br />

could serve as appropriately robust chemical biology probes and<br />

good starting points for further medicinal <strong>chemistry</strong> optimization.<br />

references:<br />

1. Lange, S. S.; Takata, K.; Wood R. D. Nat. Rev. Cancer<br />

2011, 11, 96.<br />

2. Parry, D. A.; Taricani, L. PCT Int. Appl.WO2008/063558.<br />

3. Ljungman M. Chem. Rev. 2009, 109, 2929.<br />

4. Naoki Maeda et al. Biochem. Biophys. Res. Commun.<br />

2007, 352, 390.<br />

5. Kamisuki S. et al. Bioorg.Med. Chem. 2004, 12, 5355.<br />

Keywords: Medicinal <strong>chemistry</strong>; Inhibitors; Spiro compounds;<br />

4 th <strong>EucheMs</strong> <strong>chemistry</strong> <strong>congress</strong><br />

P - 0 9 0 2<br />

SuPerBASe ProMoted StereoSeLeCtive<br />

Azetidine SyntheSiS<br />

e. KovACS 1 , G. turCzeL 1 , f. ferenC 1<br />

1 Budapest University of Technology and Economics,<br />

Department of Organic Chemistry and Technology, Budapest,<br />

Hungary<br />

Email: erkovacs@mail.bme.hu<br />

In the framework of an ongoing research project optically<br />

active 2-3-disubstituted oxetanes were prepared in our laboratory<br />

via superbase induced enantioselective rearrangements of chiral<br />

benzyloxymethyl oxiranes [1, 2] . From these oxetanes pyrrolidine<br />

derivative can be formed from in three steps [3] .<br />

Starting from that findings, our new aim was the further<br />

investigation of the stereoselective intramolecular rearrangement<br />

reaction with the intetntion to get azetidine derivatives. First we<br />

prepared oxirane derivatives which are substituted with<br />

benzylaminomethyl group instead of benzyloxymethyl function.<br />

These compounds were treated with LIDAKOR superbase.<br />

The reaction provided the desired new azetidine derivatives<br />

containing the ring substituents in trans position, exclusively. The<br />

1-methyl-2-phenyl-3-(1-(trimethylsilyloxy)-2-(trityloxy)ethyl)azetidine<br />

was prepared by TMSCl from the 1-(1-methyl-2-phenylazetidin-<br />

-3-yl)-2-(trityloxy)ethanol. Now we try to prepare pyrrolidine<br />

derivatives from this compound.<br />

The derivatives of the synthesized compounds can be<br />

valuable intermediates of drugs in pharmaceutical research [4] , and<br />

can be used as chiral ligands in enantioselective catalytic<br />

reactions.<br />

This work is connected to the scientific program of the<br />

“Development of quality-oriented and harmonized R+D+I<br />

strategy and functional model at BME” project. This project is<br />

supported by the New Hungary Development Plan (Project ID:<br />

TÁMOP-4.2.1/B-09/1/KMR-2010-0002) and was carried out in<br />

the framework of a bilateral scientific cooperation between the<br />

Hungarian Academy of Sciences and CNR Italy.<br />

references:<br />

1. A. Mordini, S. Bindi, S. Pecchi, A. Degl’Innocenti,<br />

G. Reginato, A. Serci: J.Org.Chem.,61, 4374 (1996)<br />

2. A. Thurner, F. Faigl, L. Toke, A. Mordini, M. Vallachi,<br />

G. Reginato, G. Czira: Tetrahedron, 57, 8173 (2001)<br />

3. E. Kovács, A. Thurner, F. Farkas, F. Faigl, L. Hegedus,<br />

Journal of Molecular Catalysis A, 339, 32 (2011)<br />

4. US4622327 patent<br />

Keywords: superbase; rearrangement; enantioselective<br />

synthesis; heterocycles; azetidines;<br />

AUGUst 26–30, 2012, PrAGUE, cZEcH rEPUbLIc

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!